Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors
Authors:
- 5 September 2017
- journal article
- editorial
- Published by Elsevier in Annals of Oncology
- Vol. 28 (11) , 2882-2887
Abstract
Tumor heterogeneity is a major challenge for drug development, and changes in heterogeneity are thought to contribute to anticancer treatment resistance. However, the standard diagnostic approach in clinical trials relies on analysis of a single (usually archival) sample from the primary tumor [1]. This provides limited characterization of a single tumor at initial diagnosis that is not necessarily representative of current disease status [1]. Recent studies have also highlighted challenges with intratumoral heterogeneity in advanced cancers [2, 3]. The success of targeted therapies is closely associated with identification of the target within a tumor sample. However, most tumors develop resistance due to intratumoral heterogeneity, clonal evolution, and selection pressure [1–4].Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 28 references indexed in Scilit:
- Circulating biomarkers to monitor cancer progression and treatmentComputational and Structural Biotechnology Journal, 2016
- Clinical management of breast cancer heterogeneityNature Reviews Clinical Oncology, 2015
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolutionScience Translational Medicine, 2015
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast CancerJournal of Clinical Oncology, 2014
- Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway InhibitorsMolecular Cancer Therapeutics, 2014
- Characterization of cell-free circulating DNA in plasma in patients with prostate cancerTumor Biology, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cellsDrug Resistance Updates, 2001